ADMA Biologics Reports Director Changes and Compensation Updates
Ticker: ADMA · Form: 8-K · Filed: Nov 21, 2024 · CIK: 1368514
| Field | Detail |
|---|---|
| Company | Adma Biologics, Inc. (ADMA) |
| Form Type | 8-K |
| Filed Date | Nov 21, 2024 |
| Risk Level | medium |
| Pages | 2 |
| Reading Time | 2 min |
| Sentiment | neutral |
Sentiment: neutral
Topics: management-change, compensation
TL;DR
ADMA Biologics shakes up board, adjusts exec pay.
AI Summary
On November 19, 2024, ADMA Biologics, Inc. filed an 8-K report detailing changes in its board of directors and executive compensation arrangements. The filing indicates the election of new directors and potential adjustments to compensation for certain officers, effective as of the report date.
Why It Matters
Changes in board composition and executive compensation can signal shifts in company strategy, governance, or financial outlook, impacting investor confidence.
Risk Assessment
Risk Level: medium — Changes in board and executive compensation can sometimes precede significant strategic shifts or financial adjustments, warranting closer investor scrutiny.
Key Players & Entities
- ADMA BIOLOGICS, INC. (company) — Registrant
- November 19, 2024 (date) — Date of earliest event reported
- Delaware (jurisdiction) — State of incorporation
- 465 State Route 17, Ramsey, New Jersey 07446 (address) — Principal executive offices
- 201-478-5552 (phone_number) — Registrant's telephone number
FAQ
What specific changes were made to the board of directors?
The filing indicates the election of directors, but the specific names and details of their election are not provided in this excerpt.
What are the details of the compensatory arrangements for certain officers?
The filing mentions compensatory arrangements for certain officers as an item of disclosure, but the specific details of these arrangements are not included in this excerpt.
When was the earliest event reported in this 8-K filing?
The earliest event reported in this 8-K filing was on November 19, 2024.
What is ADMA Biologics, Inc.'s state of incorporation?
ADMA Biologics, Inc. is incorporated in Delaware.
What is the address of ADMA Biologics, Inc.'s principal executive offices?
The address of ADMA Biologics, Inc.'s principal executive offices is 465 State Route 17, Ramsey, New Jersey 07446.
Filing Stats: 579 words · 2 min read · ~2 pages · Grade level 11.3 · Accepted 2024-11-21 16:30:24
Filing Documents
- ef20038782_8k.htm (8-K) — 27KB
- 0001140361-24-047487.txt ( ) — 158KB
- adma-20241119.xsd (EX-101.SCH) — 4KB
- adma-20241119_lab.xml (EX-101.LAB) — 21KB
- adma-20241119_pre.xml (EX-101.PRE) — 16KB
- ef20038782_8k_htm.xml (XML) — 4KB
02
Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. On November 19, 2024, Bryant E. Fong notified ADMA Biologics, Inc. (the "Company") that he resigned, effective immediately, as a member of the Company's Board of Directors (the "Board") and any committees of the Board in order to devote more time to his roles as Managing Director of Biomark Capital Fund and as Partner and Co-Portfolio Manager of Stonepine Capital Management. There are no disagreements between Mr. Fong and the Company on any matter relating to the Company's operations, policies or practices. Mr. Fong served as a member of the Company's Board since 2012. He also served as Chairman of the Company's Audit Committee and a member of the Company's Governance and Nominations Committee and Compensation Committee. On November 19, 2024, Young T. Kwon, PhD was appointed as Chairman of the Company's Audit Committee and designated as an "audit committee financial expert", as such term is defined in Securities and Exchange Commission rules, Steven A. Elms was added as a member of the Company's Audit Committee, and Alison C. Finger was added as a member of the Company's Governance and Nominations Committee and Compensation Committee.
01
Item 9.01 Exhibits. (d) Exhibits Exhibit No. Description 104 Cover Page Interactive Data File (embedded with the Inline XBRL document) SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. November 21, 2024 ADMA Biologics, Inc. By: /s/ Adam S. Grossman Name: Adam S. Grossman Title: President and Chief Executive Officer